Cancer Supportive Care Drugs Market Analysis

Cancer Supportive Care Drugs Market Analysis

To get key market trends

  Download Free Sample

Based on drug class, the cancer supportive care drugs market is segmented into G-CSFs (granulocyte-colony stimulating factors), ESAs (erythropoiesis stimulating agents), anti-emetics, bisphosphonates, opioids, NSAIDs, and other drug types. In 2022, the G-CSFs (granulocyte-colony stimulating factors) segment accounted for the largest share of 22.8% in the industry. The main purpose for using G-CSF is to avoid neutropenia. Chemotherapy commonly impacts rapidly dividing cells, such as neutrophils in bone marrow, resulting in decreased neutrophil numbers. G-CSFs stimulate the bone marrow to produce more neutrophils, lowering the risk of severe neutropenia and related infections. In addition, due to the increased risk of infection, neutropenia could result in chemotherapy dosage reductions, delays, or suspensions. Healthcare practitioners can follow the prescribed chemotherapy treatment to attain optimal treatment results by using G-CSFs to avoid neutropenia.
 

Based on cancer type, the cancer supportive care drugs market is segmented into breast cancer, lung cancer, melanoma, prostate cancer, colorectal cancer, liver cancer, stomach cancer, and other cancer types. The breast cancer segment held the significant industry share of around 14.1% in 2022. Breast cancer treatment often involves a combination of surgery, radiation therapy, chemotherapy, and targeted therapy. Each of these modalities can cause different side effects, such as pain, nausea, fatigue, and emotional distress. Supportive care drugs address these diverse symptoms to improve patients' overall well-being. According to National Breast Cancer Foundation, Inc. in the U.S., 1 out of 8 women will be diagnosed with breast cancer over her lifetime. An estimated 297,790 women and 2,800 men will be diagnosed with invasive breast cancer in 2023.
 

Based on distribution channel, the cancer supportive care drugs market is segmented as hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a dominant industry share of 58.9% in 2022 and is expected to grow at a CAGR of 2% by 2032. Hospital pharmacists have specialized knowledge in oncology and supportive care drugs. They collaborate with healthcare teams to ensure appropriate drug selection, dosing, and administration based on individual patient needs.
 

Asia Pacific cancer supportive care drugs market accounted for significant revenue in 2022 and is expected to reach USD 6.1 billion in 2032 with a CAGR of 2.3% from 2023-2032. The Asia Pacific region has witnessed a rising incidence of cancer, attributed to factors such as population growth, aging, changing lifestyles, and environmental factors. As cancer cases increase, so does the demand for supportive care drugs to manage treatment-related symptoms.
 

Moreover, many countries in the Asia Pacific are adopting Western-style cancer treatments, including chemotherapy and targeted therapies. These therapies often come with side effects that require effective supportive care interventions.